Meritage Pharma, a San Diego-based drug developer, said today it has started a mid-stage clinical trial of an experimental drug for an inflammatory condition of the esophagus, called eosinophilic esophagitis. The trial will enroll 80 children and young adults on three different doses of the Meritage drug or a placebo. We profiled this company’s technology in detail back in December.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
